Ginkgo accelerates widespread adoption of synthetic biology, including new partnerships with startup accelerators Y Combinator and Petri BOSTON, September 19, 2019-- Today, Ginkgo Bioworks, the organism company, announced a Series E financing round of $290 million with participation from all existing major investors and other new investors including funds and accounts advised by T. Rowe Price Associates, Inc., bringing the company's total funding to $719 million.